Peripheral Excitatory Effects of Two Enkephalinase

Total Page:16

File Type:pdf, Size:1020Kb

Peripheral Excitatory Effects of Two Enkephalinase Peripheral excitatory effects of two enkephalinase inhibitors, acetorphan and thiorphan, and an enkephalin analogue, [d-Ala2\p=n-\Met5]-enkephalinamide, on uterine motility in periparturient rats in vivo and in vitro O. Adjroud Laboratory of Feto—Maternal Physiology, University of Rouen, 76 30 Mont Saint Aignan, France The effects of two enkephalinase inhibitors, acetorphan and thiorphan, and the enkephalin analogue [d-Ala2\p=n-\Met5]-enkephalinamide (DAMEA), on spontaneous uterine contractions were studied at day 21 of pregnancy in rats following treatment in vivo or in vitro. Acetorphan (10 mg kg\m=-\1)and thiorphan (1 mg kg\m=-\1),immediately after their i.v. administration, increased the duration of spontaneous contractions 3.4- and 4.6-fold, respectively, but did not modify the maximum amplitude. Similarly, thiorphan (40 \g=m\moll\m=-\1) increased the duration of contractions when administered in vitro. Thiorphan was ineffective during the first 30 min when given into the cerebral ventricles (50 \g=m\gper rat). These results suggest that the enkephalinase inhibitors are acting via a peripheral opioid pathway; and this conclusion is supported by the observation that thiorphan potentiated the stimulatory effect of a submaximal dose of DAMEA administered in vitro. The excitatory effects of DAMEA and the enkephalinase inhibitors were blocked by naloxone. This antagonistic effect of naloxone on uterine motility in the periparturient rat uterus, induced by either acetorphan and thiorphan or DAMEA, seems to be regulated by peripheral opiate receptors. Naloxone (10 mg kg\m=-\1 s.c.) increased both the amplitude and duration of uterine motility in vivo; however, naloxone (26 \g=m\moll\m=-\1 and 52 \g=m\moll\m=-\1) produced a paradoxical dose-dependent biphasic effect in vitro. Introduction in the regulation of uterine motility. However, little informa¬ tion is available concerning the action of enkephalin on the Opioid peptides are involved in maternal adaptation to preg¬ uterine muscle in the last stage of pregnancy. The present nancy and in uterine motility. In pregnant women, plasma study was therefore undertaken to investigate the response of concentrations of ß-endorphin rise throughout pregnancy the rat myometrium to met-enkephalin on day 21 of pregnancy (Genazzani et al, 1981), and reach peak values during labour and the possible involvement of enkephalinase in this response, (Facchinetti et al, 1982; Genazzani et al, 1985). This increase in using a long lasting enkephalin analogue [D-Ala2—Met' ]- opioid peptide concentrations during labour correlates in a enkephalinamide (DAMEA) and two enkephalinase inhibitors, linear fashion with the number and density of uterine con¬ acetorphan and thiorphan. Acetorphan, a lipophilic derivative tractions (Facchinetti et al, 1982) and with response to the of thiorphan enters into the brain, where it generates thiorphan painful stimuli typical of this condition (Genazzani et al, 1985). (Roques et al, 1980, 1981). When administered in low parental Furthermore, met-enkephalin concentrations increase during doses to rats, it inhibits the cerebral enkephalinase, producing pregnancy and delivery in several brain regions of pregnant more effects than does intracerebral thiorphan (Lecomte et al, rats (Petraglia et al, 1985) and in the human placenta during 1986). Thiorphan penetrates poorly into the brain and elicits labour (Sastry et al, 1980). Similarly, opiate receptors and mainly peripheral effects. Its nanomolar potency in vitro con¬ enkephalinase, an enkephalin-degrading-enzyme at the Gly trasts with the large parental doses required to inhibit the rat - Phe bond (Malfroy et al, 1978) are present in the pregnant rat and mouse cerebral enzyme (Roques et al, 1980; Chipkin et al, uterus (Baraldi et al, 1985; Ottlecz et al, 1991) and in the 1982; Hachisu et al, 1985). In addition to their analgesie human placenta (Valette et al, 1980; Johnson et al, 1984). properties, these inhibitors partially protect the endogenous These data suggest that met-enkephalin could be involved not met-enkephalin release from brain slices and from being exten¬ only in the modulation of analgesia during pregnancy but also sively hydrolysed by enkephalinase (Patey et al, 1981; De La Baume et al, 1983) and increase the half-life of [3H]enkephalin et Central and effects of these *Present address for correspondence: Laboratory of Animal Physiology, (Chaillet al, 1983). peripheral University of Batna 0.5000, Algeria. inhibitors were assessed by comparing the stimulatory actions Revised manuscript received 9 January 1995. of i.V. acetorphan and thiorphan, or thiorphan given i.V., i.e.v. Downloaded from Bioscientifica.com at 09/27/2021 03:19:58PM via free access or in vitro. The possible involvement of enkephalinase in the equilibration for about 60 min. A 15 min recording period with modulation of uterine was studied motility by adding DAMEA sterile saline was used as a control for subsequent 15 min to the isolated tissue and attempting to protect this peptide exposures to active agents. In the bathing medium, the strip with thiorphan. Naloxone, an opiate receptor antagonist, was was washed between the addition of different drugs for at least used to block the effects induced by both inhibitors and 15 min and allowed to return to a stable baseline. DAMEA. Treatment regimens Materials and Methods Acetorphan and thiorphan, synthesized as described by Roques et al (1980, 1981), were obtained from Bioprojet Animals Labs (Paris). Naloxone and [D-Ala -Met5]-enkephalinamide (DAMEA) were purchased from Chemical Adult Wistar rats (Charles River Labs, St Aubin-les-Elbeuf) Sigma Company (St Louis, MO). Thiorphan, naloxone and DAMEA were were kept in a lighting schedule of 12 h h dark at light:12 dissolved in sterile saline and the pH was adjusted, when 23 ± 1°C with free access to food (U.A.R.103, Villemoison sur necessary, to 7.4. Acetorphan was dissolved in a vehicle and water. Females were Orge) (250-350 g body mass) caged composed of 10% ethanol, 10% Cremophor (Bioprojet Labs), with males and the smear examined for the overnight vaginal and 80% water, pH 7.4. presence of spermatozoa. The day on which spermatozoa were found in the smear was designated day 1 of pregnancy and Experiments in vivo. Thiorphan was given i.v. at 0.15, 1 animals were used at day 21. The average duration of gestation ~ ' and 5 mg kg body mass in 0.3 ml or i.c.v. at 50 µg in 20 µ . in the breeding colony was 22 days. was i.v. at 5 or 10 in ml. Acetorphan given mg kg ~ 0.3 Naloxone was used to block the effects of the enkephalinase inhibitors. Naloxone was s.c. or 10 Preparation in vivo given at 5 mg kg" body mass in 0.3 ml, 10 min before i.v. thiorphan or acetorphan. This Each animal was anaesthetized with sodium route and these doses of naloxone block the analgesic effects of ~ ' pentobarbital (45 mg kg body mass, i.p.; Abbott Laboratories, St Remy sur acetorphan and thiorphan i.v. in rat and mice nociceptive tests. Avre) and the trachea was cannulated to assist respiration. The. (Chaillet et al, 1983; Costentin et al, 1986; Lecomte et al, 1986; abdomen was opened using a midline incision and the medial Hachisu et al, 1985). part of one uterine horn was linked to an isometric strain gauge connected to an ink recording polygraph. The uterus was Experiments in vitro. The met-enkephalin analogue, secured to the strain gauge by a cotton thread passed between DAMEA, was used to reveal the presence of enkephalinase in the myometrium and the blood vessels of the mesometrial the rat uterus. DAMEA was used at i.7, 7.5 and 14.8 1 pmol " 1. end membrane. The cervical of the of the uterus that was at 10, 20 and 40 1 , was or part Thiorphan µ ~ used alone in used for recording was secured to a vertical fixed metal rod to combination with DAMEA (13 µ 1" :). Naloxone at 13, 26 : maintain isometric conditions. A standard tension of 1 was and 52 was or g µ 1 ~ used alone in combination with applied to each uterine horn and care was taken to maintain thiorphan (40 µ l-1) plus DAMEA (13 µ I"1). irrigation by dripping Tyrode's solution (pH 7.4; 36°C) down the outside of the horn. This arrangement records isometric contractions primarily of the longitudinal muscle layer. The Measurement of the spontaneous uterine contractions system was allowed to stabilize for 60 min before recordings Variations in myometrial mechanical activity were evaluated were taken for 30 min to a control value for provide compari¬ in terms of the duration and amplitude of contractions. The son with treatments. The vehicles in which the active agents maximal amplitude (mm) of each contraction was measured and were dissolved were administered the route and by appropriate the duration (s) was taken as the interval between successive in the volume at the start of the 30 min control appropriate relaxations. The amplitude and duration of each contraction Animals were then treated with the active and period. agents during the control were calculated. of 6-13 taken for 30-60 min. period Groups recordings animals were assigned to each treatment in vivo, and each treatment in vitro was performed on at least 6-7 separate preparations. Each recording of the treatment in vivo lasted Isolated preparation in vitro 30-60 min. This time was divided into 10 min periods. The means sem the Each animal was killed with an overdose of pentobarbital ± of amplitude and duration of contractions of each and the uterine horn was split longitudinally. A 40 mm group of treated animals were calculated at 10 min 5 mm uterine strip was removed, as described by Singh and periods during 30-60 min of recording.
Recommended publications
  • Methadone Hydrochloride Tablets, USP) 5 Mg, 10 Mg Rx Only
    ROXANE LABORATORIES, INC. Columbus, OH 43216 DOLOPHINE® HYDROCHLORIDE CII (Methadone Hydrochloride Tablets, USP) 5 mg, 10 mg Rx Only Deaths, cardiac and respiratory, have been reported during initiation and conversion of pain patients to methadone treatment from treatment with other opioid agonists. It is critical to understand the pharmacokinetics of methadone when converting patients from other opioids (see DOSAGE AND ADMINISTRATION). Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration. Respiratory depression is the chief hazard associated with methadone hydrochloride administration. Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects, particularly in the early dosing period. These characteristics can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration. In addition, cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Methadone treatment for analgesic therapy in patients with acute or chronic pain should only be initiated if the potential analgesic or palliative care benefit of treatment with methadone is considered and outweighs the risks. Conditions For Distribution And Use Of Methadone Products For The Treatment Of Opioid Addiction Code of Federal Regulations, Title 42, Sec 8 Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority.
    [Show full text]
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • The Opioid Epidemic: What Labs Have to Do with It?
    The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 1 Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 2 Analysis. Answers. Action. www.aphl.org Opiates and Opioids • Opiates vs. Opioids • Opiates: Naturally occurring, derived from the poppy plant • Opioids: “Opiate-like” drugs in effects, not chemical structure Includes opiates • Narcotic analgesics • CNS depressants • DEA Schedule I or II controlled substances • Additive effect with other CNS depressant drugs Analysis. Answers. Action. www.aphl.org Efficacy of Opioids • How do opioids work? • Bind with opioid receptors • Brain, spinal cord, GI tract, and throughout the body • Pain, emotion, breathing, movement, and digestion Opioid Receptor Analysis. Answers. Action. www.aphl.org Effects of Opioids Physiological Psychological • Pain relief • Drowsiness/ sedation • Cough suppression • Mental confusion • GI motility • Loss of memory • Respiratory depression • Lethargy/ apathy • Pupillary constriction • Euphoria/ tranquility • Itching • Mood swings • Constipation • Depression • Dependence • Withdrawal • Dependence Analysis. Answers. Action. www.aphl.org Opiates 1 Opiates • Naturally occurring alkaloids Opium • Latex from the opium poppy plant Codeine: • Mild to moderate pain • Antitussive Morphine: • Severe pain • Metabolite of codeine and heroin Analysis. Answers. Action. www.aphl.org Opiates 2 Semi-synthetic Opiates: • Synthesized from a natural opiate Heroin: • Schedule I narcotic Hydrocodone (Vicodin): • Mild to moderate pain • Metabolizes to hydromorphone (Dilaudid) Oxycodone (Oxycontin/Percocet): • Moderate to severe pain • Metabolizes to oxymorphone (Opana) Analysis. Answers. Action.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Enkephalin Degradation in Serum of Patients with Inflammatory Bowel Diseases
    Pharmacological Reports 71 (2019) 42–47 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Enkephalin degradation in serum of patients with inflammatory bowel diseases a, a b Beata Wilenska *, Dagmara Tymecka , Marcin Włodarczyk , b c Aleksandra Sobolewska-Włodarczyk , Maria Wisniewska-Jarosinska , d e b a,d, Jolanta Dyniewicz , Árpád Somogyi , Jakub Fichna , Aleksandra Misicka * a Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warszawa, Poland b Department of Biochemistry, Medical University of Lodz, Łódz, Poland c Department of Gastroenterology, Medical University of Lodz, Łódz, Poland d Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Science, Warszawa, Poland e Campus Chemical Instrumentation Centre (CCIC), The Ohio State University, Columbus, OH, USA A R T I C L E I N F O A B S T R A C T Article history: Background: Inflammatory bowel diseases (IBD) are a group of chronic and recurrent gastrointestinal Received 18 April 2018 disorders that are difficult to control. Recently, a new IBD therapy based on the targeting of the Received in revised form 10 June 2018 endogenous opioid system has been proposed. Consequently, due to the fact that endogenous Accepted 1 August 2018 enkephalins have an anti-inflammatory effect, we aimed at investigating the degradation of serum Available online 2 August 2018 enkephalin (Met- and Leu-enkephalin) in patients with IBD. Methods: Enkephalin degradation in serum of patients with IBD was characterized using mass Keywords: spectrometry methods. Calculated half-life (T1/2) of enkephalins were compared and correlated with the Inflammatory bowel diseases disease type and gender of the patients.
    [Show full text]
  • Opiate/ Heroin Working Group Final Report
    OPIATE/ HEROIN WORKING GROUP FINAL REPORT United States Attorney’s Offices For the Southern and Northern Districts of Mississippi February 28. 2017 HEROIN/OPIATE WORKING GROUP FINAL REPORT Law Enforcement and Data Group Recommendation No. 1: Implement a comprehensive data collection and dissemination program Recommendation No. 2: Heroin (Opiate) Involved Death Investigation Task Force Recommendation No. 3: Greater distribution and training on use of Naloxone Recommendation No. 4: Mandate greater reporting of overdoses and naloxone administration Recommendation No. 5: Expand and advertise availability of the dropbox program Medical Issues Group Recommendation No. 1: Adopt CDC Guidelines Recommendation No. 2: Continuing Medical Education Recommendation No. 3: Upgrades to the Prescription Monitoring Program Recommendation No. 4: Addiction Treatment Education Recommendation No. 5: Review Funding Issues for Alternative Treatments Recommendation No. 6: Limitations on Prescriptions Recommendation No. 7: Mandate increased use of PMP Recommendation No. 8: Change the definition of Pain Management Clinic Recommendation No. 9: IDs for Controlled Substance Prescriptions Treatment and Overdose Prevention Group Recommendation No. 1: More Funding for Treatment Recommendation No. 2: Youth/Juvenile Detention Systems Recommendation No. 3: Expand the availability and use of Vivitrol Recommendation No. 4: Drug Courts and Rentry programs Recommendation No. 5: Public Education and Awareness HEROIN/OPIATE WORKING GROUP FINAL REPORT The United States Attorney’s Offices for the Northern and Southern Districts of Mississippi convened an Opiate/Heroin Working Group in June 2016. At the initial meeting at the Mississippi Bureau of Narcotics (“MBN”) Headquarters, representatives from the medical, pharmaceutical, mental health, law enforcement, judiciary and many other specialties attended a full day symposium to begin the discussion about a comprehensive approach to the opiate and heroin crisis in the nation and in our state.
    [Show full text]
  • PRODUCT INFORMATION Spinorphin Item No
    PRODUCT INFORMATION Spinorphin Item No. 29914 NH CAS Registry No.: 137201-62-8 Formal Name: L-leucyl-L-valyl-L-valyl-L-tyrosyl-L- O H O N prolyl-L-tryptophyl-L-threonine N OH O N H Synonyms: Leu-Val-Val-Tyr-Pro-Trp-Thr, O OH H LVVYPWT O O N MF: C45H64N8O10 N N O FW: 877.0 H H NH2 Purity: ≥95% UV/Vis.: λmax: 222 nm Supplied as: A crystalline solid Storage: -20°C OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Spinorphin is supplied as a crystalline solid. A stock solution may be made by dissolving the spinorphin in the solvent of choice, which should be purged with an inert gas. Spinorphin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of spinorphin in these solvents is approximately 30 mg/ml. Description Spinorphin is a heptapeptide inhibitor of the enkephalin-degrading enzymes aminopeptidase, dipeptidyl aminopeptidase, angiotensin-converting enzyme (ACE), and enkephalinase (IC50s = 3.3, 1.4, 2.4, and 10 µg/ml, respectively, for monkey brain enzymes).1 It is selective for these enzymes over human serum aminopeptidase A (IC50 = >100 µg/ml), as well as porcine kidney aminopeptidase B, aminopeptidase M, dipeptidyl peptidase 1 (DPP-1), DPP-2, DPP-3, and DPP-4 (IC50s = >55 µg/ml for all). Spinorphin inhibits chemotaxis, production of reactive oxygen species (ROS), and exocytosis of glucuronidase and collagenase in polymorphonuclear neutrophils (PMNs). It potentiates enkephalin-induced action potentials in rat hippocampal slices.
    [Show full text]
  • Review Article Role of Antidiarrhoeal Drugs As Adjunctive Therapies for Acute Diarrhoea in Children
    Hindawi Publishing Corporation International Journal of Pediatrics Volume 2013, Article ID 612403, 14 pages http://dx.doi.org/10.1155/2013/612403 Review Article Role of Antidiarrhoeal Drugs as Adjunctive Therapies for Acute Diarrhoea in Children Christophe Faure Division of Gastroenterology, Department of Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada H3T 1C5 Correspondence should be addressed to Christophe Faure; [email protected] Received 25 October 2012; Revised 2 January 2013; Accepted 2 January 2013 Academic Editor: Catherine Bollard Copyright © 2013 Christophe Faure. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Acute diarrhoea is a leading cause of child mortality in developing countries. Principal pathogens include Escherichia coli, rotaviruses, and noroviruses. 90% of diarrhoeal deaths are attributable to inadequate sanitation. Acute diarrhoea is the second leading cause of overall childhood mortality and accounts for 18% of deaths among children under five. In 2004 an estimated 1.5 million children died from diarrhoea, with 80% of deaths occurring before the age of two. Treatment goals are to prevent dehydration and nutritional damage and to reduce duration and severity of diarrhoeal episodes. The recommended therapeutic regimen is to provide oral rehydration solutions (ORS) and to continue feeding. Although ORS effectively mitigates dehydration, it has no effect on the duration, severity, or frequency of diarrhoeal episodes. Adjuvant therapy with micronutrients, probiotics, or antidiarrhoeal agents may thus be useful. The WHO recommends the use of zinc tablets in association with ORS.The ESPGHAN/ESPID treatment guidelines consider the use of racecadotril, diosmectite, or probiotics as possible adjunctive therapy to ORS.
    [Show full text]
  • Drug Class Review Long-Acting Opioid Analgesics
    Drug Class Review Long-Acting Opioid Analgesics 28:08.08 Opiate Agonists Transdermal Buprenorphine transdermal system (Butrans®) Fentanyl transdermal system (Duragesic®) Oral Buprenorphine oral buccal film (Belbuca®) Hydrocodone ER (Zohydro ER®, Hysingla ER®) Hydromorphone hydrochloride extended-release tablets (Exalgo®) Methadone tablets (Dolophine®) Morphine sulfate controlled-release tablets (MS Contin®, MorphaBond®) Morphine sulfate extended-release capsules (Kadian®) Oxycodone hydrochloride controlled-release tablets (OxyContin®) Oxymorphone hydrochloride extended-release (Opana ER®) Tapentadol extended-release oral tablets (Nucynta ER®) Tramadol hydrochloride extended-release capsule (Conzip, others) Tramadol hydrochloride extended-release tablet (biphasic) (Ultram ER, others) Combination Products Morphine sulfate and naltrexone extended-release capsules (Embeda®) Oxycodone ER/acetaminophen (Xartemis XR®) Final Report March 2016 Review prepared by: Vicki Frydrych, Clinical Pharmacist Melissa Archer, Clinical Pharmacist Justin Tran, PharmD Student Ryan Marcum, PharmD Student University of Utah College of Pharmacy Copyright © 2016 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ........................................................................................................................ 3 Introduction ..................................................................................................................................... 5 Table 1. Comparison
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • Neprilysin Controls the Synaptic Activity of Neuropeptides in the Intercalated Cells of the Amygdala
    Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Neprilysin controls the synaptic activity of neuropeptides in the intercalated cells of the amygdala Authors: Gregoriou GC, Patel SD, Winters BL, Bagley EE Primary laboratory of origin: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, Downloaded from University of Sydney, Camperdown, NSW, 2006, Australia. molpharm.aspetjournals.org at ASPET Journals on October 1, 2021 1 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Running title: Neuropeptides degradation in the amygdala Corresponding author: Elena Bagley Address: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, University of Sydney, Camperdown, NSW, 2006, Australia. Telephone: 61 2 93514895 Fax: N/A E-mail: [email protected] Number of pages: 31 Downloaded from Number of figures: 3 Number of references: 56 Words in abstract: 245 molpharm.aspetjournals.org Words in introduction: 486 Words in discussion: 844 Abbreviations: at ASPET Journals on October 1, 2021 ACE: angiotensin-converting enzyme ACSF: artificial cerebrospinal fluid APN: aminopeptidase N BLA: basolateral amygdala CNS: central nervous system DOR: δ-opioid receptor EPSC: excitatory post‐synaptic currents MOR: µ-opioid receptor met-enk: methione enkephalin NEP: neprilysin N/OFQ: Nociceptin/Orphanin FQ PI: peptidase inhibitors PPR: paired pulse ratio 2 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted.
    [Show full text]